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esponse to publications by Heyward W
t al. and Kuan R et al.: Clinical and cost-
ffectiveness analyses, respectively, of hepatitis
 vaccination—HeplisavTM compared with
ngerix-B® vaccine in adults
esponse
We  thank Vaccine for providing the opportunity to respond to
he articles from Heyward et al. and Kuan et al. From a clinical per-
pective, seroprotection rates above 90% are reported in healthy
ndividuals aged 12–70 years immunized with Engerix-B® using
 3-dose vaccination schedule [1,2]. In particular, seroprotection
ates of 91% were reported in a United States population aged 39–70
ears of age [1]. Several factors have been identiﬁed that are asso-
iated with suboptimal responses, including age and body mass
ndex [2]. The study of Heyward et al. combines 2 of these factors,
amely a mean age of 54 years and a mean BMI  of 30 kg/m2, which
ay  partly explain the low sero-protection rate of Engerix-B®. As
uch, the results of Heyward et al., demonstrating superior sero-
rotection rates for HepislavTM than Engerix-B® in older adults and
bese persons, may  not generalize to other populations [2], such as
ounger people or adults with lower BMI  levels.
The vaccine efﬁcacy inputs in the CE model come from 2 pivotal
rials conducted on populations of different ages, but an age-
nweighted average value has been introduced into the model,
hich may  affect the end results given that age has an impact on
he vaccine efﬁcacy [3]. Data inputs were chosen from references
hat are not representative for the population studied in the model.
n addition, other appropriate references with peer-reviewed data
ere omitted (e.g. Table 1 in Hoerger et al. reported a transi-
ion probability from acute to chronic of 6% for diabetic subjects,
hereas 12.3% was used here) [4].
Miscalculations may  have occurred in transposing rates into
robabilities as presented in Table 2. For instance, in the paper by
aniels et al., a rate of 2.7/100,000 per year is reported from transi-
ioning from susceptible to acute hepatitis-B health states, whereas
his paper reported numbers with one decimal less: i.e., 0.027% [5].
f this inconsistency can be explained by the inclusion of an under-
eporting factor, then this should be documented. Also, different
esource use and costs should be applied: e.g., unreported asymp-
omatic cases (with no costs), unreported symptomatic cases (with
ittle costs) and reported symptomatic cases (with reported costs).
In addition, we believe that some results of the analysis seem
nrealistic. As illustrated in Supplementary Figure 1, subjects can
nly move to the health state “Chronic HBV Infection” from the
ealth state “Acute HBV Infection”. Therefore, subjects who develop
hronic infection are a subset of those who develop acute infec-
ions. As such, it does not seem possible to prevent more cases
f chronic infections than acute infections as reported in Table 4.
lso for example, with an annual infection rate of 0.2% in suscep-
ible individuals with CKD who are 45 years and older, it seems
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.033
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unimpossible that 3706 additional acute cases could be avoided by
vaccinating with HeplisavTM instead of Engerix-B®.
Finally, given the model assumptions, it is surprising that in
the sensitivity analysis adherence to the 3rd dose and the vaccine
efﬁcacy of Engerix-B®, for which much higher values have been
reported elsewhere, are not among the most sensitive parameters
[1,2]. It is interesting to note that in Supplementary Table 4, the
CE ratio for HeplisavTM is not more sensitive to lower HeplisavTM
efﬁcacy estimates (e.g. 44%).
Therefore, the results of these analyses should be interpreted
with caution.
Trademarks
Engerix-B® is a registered trademark of the GlaxoSmithKline
group of companies.
HeplisavTM is a trademark of Dynavax Technologies Corpora-
tion, USA.
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